|
?:abstract
|
-
Background: There are limited data on COVID-19 in patients with cancer We characterize the outcomes of patients with cancer and COVID-19 and identify potential prognostic factors Methods: The COVID- 19 and Cancer Consortium (CCC19) cohort study includes patients with active or prior hematologic or invasive solid malignancies reported across academic and community sites Results: We included 1,018 cases accrued March-April 2020 Median age was 66 years (range, 18-90) Breast (20%) and prostate (16%) cancers were most prevalent;43% of patients were on active anti-cancer treatment At time of data analysis, 106 patients (10 4%) have died and 26% met the composite outcome of death, severe illness requiring hospitalization, and/or mechanical ventilation In multivariable logistic regression analysis, independent factors associated with increased 30- day mortality were age, male sex, former smoking, ECOG performance status (2 versus 0/1: partially adjusted odds ratio (pAOR) 2 74, 95% CI 1 31-5 7;3/4 versus 0/1: pAOR 5 34, 95% CI 2 44-11 69), active malignancy (stable/responding, pAOR 1 93, 95% CI 1 06-3 5;progressing, pAOR 3 79, 95% CI 1 78-8 08), and receipt of azithromycin and hydroxychloroquine Tumor type, race/ethnicity, obesity, number of comorbidities, recent surgery, and type of active cancer therapy were not significant factors for mortality Conclusions: All-cause 30-day mortality and severe illness in this cohort were significantly higher than previously reported for the general population and were associated with general risk factors as well as those unique to patients with cancer Cancer type and treatment were not independently associated with increased 30-day mortality Longer follow-up is needed to better understand the impact of COVID-19 on outcomes in patients with cancer, including the ability to continue specific cancer treatments
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}